1. Home
  2. TGTX vs MANH Comparison

TGTX vs MANH Comparison

Compare TGTX & MANH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$53.25

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Logo Manhattan Associates Inc.

MANH

Manhattan Associates Inc.

HOLD

Current Price

$213.75

Market Cap

8.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGTX
MANH
Founded
1993
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
8.2B
IPO Year
2008
1998

Fundamental Metrics

Financial Performance
Metric
TGTX
MANH
Price
$53.25
$213.75
Analyst Decision
Strong Buy
Buy
Analyst Count
5
11
Target Price
$49.80
$209.73
AVG Volume (30 Days)
1.9M
682.7K
Earning Date
05-04-2026
04-21-2026
Dividend Yield
N/A
N/A
EPS Growth
1746.67
2.56
EPS
0.12
0.82
Revenue
$2,785,000.00
$131,300,000.00
Revenue This Year
$49.08
$8.10
Revenue Next Year
$26.69
$8.81
P/E Ratio
$457.29
$205.01
Revenue Growth
N/A
N/A
52 Week Low
$25.37
$119.06
52 Week High
$59.30
$227.43

Technical Indicators

Market Signals
Indicator
TGTX
MANH
Relative Strength Index (RSI) 51.91 79.83
Support Level $51.15 $167.26
Resistance Level $58.34 N/A
Average True Range (ATR) 2.23 8.57
MACD -0.57 3.24
Stochastic Oscillator 36.41 98.01

Price Performance

Historical Comparison
TGTX
MANH

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

About MANH Manhattan Associates Inc.

Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers worldwide.

Share on Social Networks: